Psychiatric morbidity and quality of life in children and adolescents with cystic fibrosis

Abstract

Şenses-Dinç G, Özçelik U, Çak T, Doğru-Ersöz D, Çöp E, Yalçın E, Çengel-Kültür E, Pekcan S, Kiper N, Ünal F. Psychiatric morbidity and quality of life in children and adolescents with cystic fibrosis. Turk J Pediatr 2018; 60: 32-40. The aim of this study was to investigate psychiatric disorders, depression and anxiety levels, and quality of life in children and adolescents with cystic fibrosis (CF), and to compare them with those of children with non-cystic fibrosis (non-CF) bronchiectasis and healthy controls. A total of 103 children and adolescents aged 7-16 years (35 CF, 28 non-CF bronchiectasis, 40 healthy) were evaluated using The Schedule for Affective Disorders and Schizophrenia for School Aged Children (K-SADS), The Child Depression Inventory (CDI), The State-Trait Anxiety Inventories for Children (STAI-C) and the Pediatric Quality of Life Inventory (PedsQL)-C. The three groups were not statistically different with respect to age, sex, and familial sociodemographic variables. 80% of the children and adolescents in the CF group were diagnosed with a psychiatric disorder, which was significantly more compared to those of the two other groups. The CF group had significantly greater rates of depressive and oppositional defiant disorder and the non-bronchiectasis group had a significantly greater rate of anxiety disorder than the control group. The depression and anxiety symptom levels were significantly greater and the quality of life levels significantly lower in both the CF and non-CF bronchiectasis groups than the healthy controls. In the CF group, the presence of any associated psychiatric disorder led to significantly lower total and psychosocial quality of life scores. In conclusion, CF is associated with poorer QOL in childhood. In order to improve quality of life in CF, the psychiatric conditions of children and adolescents should also be evaluated and their follow-up and treatment should involve a multidisciplinary team approach.

Effect of COVID-19 Pandemic on Anxiety Levels of Children with Cystic Fibrosis and Healthy Children

“…Previous meta-analyses and systematic reviews have shown that adults and children with chronic diseases have higher risk of depression and anxiety compared to community [2,3]. A number of studies reported increased anxiety and depression in CF pateints compared to healthy controls [4][5][6]. Facing a chronic disease such as CF on a daily basis cause significant emotional burden which can be attributed to large number of treatments, hospitalizations, multiple diagnostic procedures, chronic respiratory symptoms, a lower body mass index [6].…”

“…During COVID-19 pandemic people are likely to experience fear of falling sick, dying or feelings of helplessness and a number of studies revealed a wide range of psychosocial impacts on people [4]. In a study by Wang et al, included 1210 respondents, psychological impact of the outbreak was present in 53.8%.…”

Starting early: An international focus on mental health in children living with cystic fibrosis

“…A recent study of 35 children with CF ages 7 to 16 (mean 13 years) from a different Turkish center, although not reporting preadolescent findings separately, bolsters the Gundogdu data: 80% were diagnosed with ≥1 psychiatric disorder using the KSADS, significantly higher than both a control group with nonCF bronchiectasis (50%) and healthy controls (20%); anxiety (54.3%), depression (20%) and ADHD (17.1%) were most common . Given regional disparities in resources supporting the delivery of care to sustain physical and psychological functioning in individuals with CF, it is essential to consider the impact of differences in healthcare systems and culture.…”

Screening of depression and anxiety in adolescents with cystic fibrosis and caregivers in Turkey by PHQ‐9 and GAD‐7 questionnaires

“…The score ranges for anxiety and depressive symptom severity in results of both PHQ-9 and GAD-7 are as follows: no symptoms (1-4), mild (5-9), moderate (10)(11)(12)(13)(14)(15), and severe (15+) symptoms. CFF/ ECFS guideline recommends supportive interventions and rescreening in the next clinical visit for patients with mild symptoms.…”